To report and discuss the multi-domain impact of elosulfase alfa , with focus on tertiary and composite endpoints , in the 24-week , randomized , double-blind , placebo-controlled phase 3 trial in patients with Morquio A syndrome ( mucopolysaccharidosis IVA ) .